PASG

Conviction 17HealthcareScan · Thu, Jun 25, 2026

PASG$4.38-25.60%

ResistanceSupportVol 14

Vol MA14 124.96K

Mar 26Apr 14May 1May 19Jun 8Jun 25

Passage BIO, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.passagebio.com ↗

Price4.38

Change-25.60%

Gap-16.58%

Rel volume1.41×

Avg volume99.76K

Avg $ vol568.34K

SMA 205.62

SMA 505.77

SMA 2008.38

Price vs 50-24.18%

Price vs 200-47.79%

MA stackbearish

50/200 cross—

Supertrenddown · 6.14

RSI (14)35

MACD hist-0.03

MACD crossbear · 0d

Stoch %K / %D36 / 65

ADX (14)18

+DI / −DI13 / 39

RSI divergence—

MACD divergence—

ATR %+14.43%

ADR %9.05%

52w high19.85

52w low0.3260

From 52w high-77.96%

Above 52w low+1242.02%

New 52w highNo

SqueezeOn · 12d

Bollinger width26.24%

%B-0.34

Donchian pos35.62%

Donchian high6.30

Donchian low3.31

AVWAP (52w high)7.69

vs AVWAP high-43.13%

AVWAP (52w low)5.43

vs AVWAP low-19.49%

OBV trendDown

Chaikin MF (20)-0.26

Today vs 20d1.41×

Avg vol (14d)124.96K

Avg vol (20d)99.76K

Avg $ vol (20d)568.34K

Market cap14.03M

RS 3m (vs SPY)-24.36%

RS 6m (vs SPY)-46.42%

RS line new highNo

Trend template2/8

Technical rank5.8

1 week-17.92%

1 month-21.17%

3 months-38.34%

6 months-56.21%

1 year+1144.31%

YTD-62.57%

P/E-0.31

P/B1.19

P/S—

P/FCF-0.44

EPS-14.35

Div yield—

ROE-387.36%

ROA-124.85%

Debt/Eq—

Current1.73

EV/EBITDA0.40

Gross margin—

Net margin—

Rev growth—

EPS growth29.71%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value-19.3M

Revenue—

Net income-7.56M

Gross profit—

Free cash flow-31.54M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out3.21M

Employees24

ListedFri, Feb 28, 2020

Free float2.84M

Float %88.7%

Short interest121.98K

Days to cover3.6d

Short volume39.8%

Squeeze score33 / 100

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction17 / 100

Pattern quality—

Tech rank5.8 / 100

Group rank50 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance6.00

Support4.43

Days since event—

Candle confirm—

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in PASG

All disclosures →

No recent disclosed trades by Congress in PASG. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in PASG · 6 buys

Insider	Side	Shares	Value	Traded	Filed
GOWEN MAXINE Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21
Porter Derrell Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21
Kassberg Thomas Richard Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21
Countouriotis Athena Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21
Sondhi Dolan Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21
Kapadia Sandip Director · Director Stock Option (right to buy) · 2026-05-19	Grant	10.54K	$0	2026-05-19	2026-05-21

SEC filings

EDGAR filings in PASG · 4 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.